3-drug combo shows promise for treating SOD1-ALS: Mouse study
A combination of three drugs — one of them the experimental therapy CuATSM — may be effective for treating…
Articles by Marisa Wexler, MS
CREB3 protein identified as potential treatment target in ALS
A rare mutation that leads to abnormally high activity of the CREB3 protein is associated with a reduced risk of…
New method may serve as platform for creating cell therapies for ALS
Scientists have developed a novel method to efficiently grow motor neurons from skin cells, which may serve as a platform…
Legislation seeks access to benefits for spouses of veterans with ALS
A bipartisan team of lawmakers in the U.S. House of Representatives and Senate is pushing for legislation to help ensure…
Using NfL biomarker could improve ALS diagnosis, prognosis: Study
Measuring blood levels of neurofilament light chain, or NfL, a biomarker of nerve damage, may help in diagnosing amyotrophic…
Fat molecules may limit damage to nerve cells in ALS, study finds
Fat molecules called polyunsaturated fatty acids, or PUFAs, can help lessen nerve damage in amyotrophic lateral sclerosis (ALS), according…
Results published for first 4 drugs in HEALEY trial; 2 to be tested further
Four experimental treatments for amyotrophic lateral sclerosis (ALS) have been tested in the HEALEY ALS platform trial and two,…
Sleep problems may develop years before ALS motor symptoms: Study
Sleep problems may become evident in people with amyotrophic lateral sclerosis (ALS) several years before the characteristic motor symptoms…
IFB-088 slows disease progression in bulbar-onset ALS trial
Oral therapy IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with amyotrophic lateral sclerosis (ALS),…
AMT-162 gene therapy trial for SOD1-ALS set for next dose group
uniQure is planning to start enrolling patients in a second dose group as part of a clinical trial testing…